Demonstration of a Common DPhe7 to DNal(2′)7 Peptide Ligand Antagonist Switch for Melanocortin‑3 and Melanocortin‑4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of...

MLA

Gimenez, Luis E., et al. “Demonstration of a Common DPhe7 to DNal(2′)7 Peptide Ligand Antagonist Switch for Melanocortin‑3 and Melanocortin‑4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties Of..” Journal of Medicinal Chemistry, vol. 65, no. 8, Apr. 2022, pp. 5990–6000. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.1c01295.

APA

Gimenez, L. E., Noblin, T. A., Williams, S. Y., Mullick Bagchi, S., Ji, R.-L., Tao, Y.-X., Jeppesen, C. B., Conde-Frieboes, K. W., Sawyer, T. K., Grieco, P., & Cone, R. D. (2022). Demonstration of a Common DPhe7 to DNal(2′)7 Peptide Ligand Antagonist Switch for Melanocortin‑3 and Melanocortin‑4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of.. Journal of Medicinal Chemistry, 65(8), 5990–6000. https://doi.org/10.1021/acs.jmedchem.1c01295

Chicago

Gimenez, Luis E., Terry A. Noblin, Savannah Y. Williams, Satarupa Mullick Bagchi, Ren-Lei Ji, Ya-Xiong Tao, Claus B. Jeppesen, et al. 2022. “Demonstration of a Common DPhe7 to DNal(2′)7 Peptide Ligand Antagonist Switch for Melanocortin‑3 and Melanocortin‑4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties Of..” Journal of Medicinal Chemistry 65 (8): 5990–6000. doi:10.1021/acs.jmedchem.1c01295.